219 related articles for article (PubMed ID: 38693435)
1. Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms.
Ferencz B; Török K; Pipek O; Fillinger J; Csende K; Lantos A; Černeková R; Mitták M; Škarda J; Delongová P; Megyesfalvi E; Schelch K; Lang C; Solta A; Boettiger K; Brcic L; Lindenmann J; Rényi-Vámos F; Aigner C; Berta J; Megyesfalvi Z; Döme B
Cancer Immunol Immunother; 2024 May; 73(6):114. PubMed ID: 38693435
[TBL] [Abstract][Full Text] [Related]
2. Comparative expression analysis of immune-related markers in surgically resected lung neuroendocrine neoplasms.
Ferencz B; Megyesfalvi Z; Csende K; Fillinger J; Poór V; Lantos A; Pipek O; Sólyom-Tisza A; Rényi-Vámos F; Schelch K; Lang C; Schwendenwein A; Boettiger K; László V; Hoetzenecker K; Döme B; Berta J
Lung Cancer; 2023 Jul; 181():107263. PubMed ID: 37270937
[TBL] [Abstract][Full Text] [Related]
3. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
Zhu MMT; Burugu S; Gao D; Yu J; Kos Z; Leung S; Horst BA; Nielsen TO
Mod Pathol; 2020 Sep; 33(9):1753-1763. PubMed ID: 32350416
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
[TBL] [Abstract][Full Text] [Related]
6. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
[TBL] [Abstract][Full Text] [Related]
7. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
9. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.
Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G
Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
[TBL] [Abstract][Full Text] [Related]
11. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung.
Beasley MB; Lantuejoul S; Abbondanzo S; Chu WS; Hasleton PS; Travis WD; Brambilla E
Hum Pathol; 2003 Feb; 34(2):136-42. PubMed ID: 12612881
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in neuroendocrine tumors of the lung.
Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
[TBL] [Abstract][Full Text] [Related]
13. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
[TBL] [Abstract][Full Text] [Related]
14. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
15. Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.
Villarroel-Espindola F; Yu X; Datar I; Mani N; Sanmamed M; Velcheti V; Syrigos K; Toki M; Zhao H; Chen L; Herbst RS; Schalper KA
Clin Cancer Res; 2018 Apr; 24(7):1562-1573. PubMed ID: 29203588
[No Abstract] [Full Text] [Related]
16. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms.
Gürler F; Aktürk Esen S; Kurt İnci B; Sütçüoğlu O; Uçar G; Akdoğan O; Uncu D; Turhan N; Akyürek N; Özdemir N; Özet A; Yazıcı O
Cancer Invest; 2024 Feb; 42(2):141-154. PubMed ID: 38486421
[TBL] [Abstract][Full Text] [Related]
18. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
19. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
